BMRN vs BBIO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
BMRN · Biomarin Pharmaceutical$60.41 ▼ 1.64%
BBIO · BridgeBio Pharma$76.03 ▼ 2.75%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- BMRN +8.8%
- BBIO +7.1%
Head to head
| Metric | BMRN | BBIO |
|---|---|---|
| Price | $60.41 | $76.03 |
| Change today | ▼ 1.64% | ▼ 2.75% |
| Market cap | $11.70B | $14.81B |
| Return, 3 months | -7.2% | -6.2% |
| Return, year to date | +1.6% | -0.6% |
| Return, 1 year | +10.5% | +11.6% |
| P/E (TTM) | – | – |
| P/B | 1.9 | -5.7 |
| P/E percentile vs own 5y | 0th | 1st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +32.0% | +192.6% |
| Net profit growth (YoY) | -299.5% | +67.3% |
| Gross margin | 76.0% | 94.3% |
| Operating margin | 4.9% | -37.3% |
| Net margin | -0.5% | -62.6% |
| Return on equity | -0.3% | – |
| Analyst target vs. price | +46.9% | +44.7% |
| Analyst buy share | 74% | 94% |
| RSI (14) | 59 | 55 |
| 30-day volatility | 31.8% | 37.8% |
| Max drawdown, 1 year | -22.6% | -29.8% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BBIO is the largest of the group by market value.
- BBIO has returned the most over the past year.
- BBIO is growing revenue fastest.
- BMRN keeps the most profit per dollar of sales.
- BMRN has been the calmest stock over the last 30 days.